Correlation Between Humacyte and Candel Therapeutics

Can any of the company-specific risk be diversified away by investing in both Humacyte and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Humacyte and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Humacyte and Candel Therapeutics, you can compare the effects of market volatilities on Humacyte and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Humacyte with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Humacyte and Candel Therapeutics.

Diversification Opportunities for Humacyte and Candel Therapeutics

0.24

Correlation Coefficient

Humacyte  Candel Therapeutics

Modest diversification

The 3 months correlation between Humacyte and Candel is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Humacyte and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Humacyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Humacyte are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Humacyte i.e., Humacyte and Candel Therapeutics go up and down completely randomly.

Pair Corralation between Humacyte and Candel Therapeutics

Assuming the 90 days horizon Humacyte is expected to under-perform the Candel Therapeutics. In addition to that, Humacyte is 1.14 times more volatile than Candel Therapeutics. It trades about -0.06 of its total potential returns per unit of risk. Candel Therapeutics is currently generating about 0.03 per unit of volatility. If you would invest  465.00  in Candel Therapeutics on September 12, 2024 and sell it today you would lose (4.00) from holding Candel Therapeutics or give up 0.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Humacyte  vs.  Candel Therapeutics

Humacyte

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Humacyte is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Candel Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Humacyte and Candel Therapeutics

The main advantage of trading using opposite Humacyte and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Humacyte position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.

The idea behind Humacyte and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.